1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsTB/MDR-TB Research Capacity Building in LMICs in Southeast Asia Phase II is sponsored by Fogarty International Center at the U.S. National Institutes of Health (NIH). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
TB/MDR-TB Research Capacity Building in LMICs in Southeast Asia Phase II - Fogarty International Center @ NIH TB/MDR-TB Research Capacity Building in LMICs in Southeast Asia Phase II Search and filter all Fogarty grants Search all NIH grants and grantees using NIH RePORTER The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Global Infectious Diseases (GID) Project Information in NIH RePORTER TB/MDR-TB Research Capacity Building in LMICs in Southeast Asia Phase II Prince of Songkla University, Thailand Principal Investigator(s) (PI) Chongsuvivatwong, Virasakdi; Chaiprasert, Angkana Project Contact Information Email: cvirasak@gmail.
com Thailand ; Burma (Myanmar) ; Indonesia Department of Medical Research University of Public Health University of Community Health University of North Sumatra National TB Program and Department of Medical Science Within the tuberculosis (TB) endemic areas in Southeast Asia, Prince of Songkla University and Mahidol University, Thailand and Methodist Hospital, Houston, Texas, will provide a degree- granting and research training program related to the epidemiology of TB, to build research and disease control capacity in Myanmar, Indonesia, and Thailand.
The Fogarty International Center's support will allow the regional network of institutes to strengthen their capacity, especially on human resources for research. After five years of the program, there will be altogether 56 researchers from these three countries trained at Doctoral, Master, and short- course level. Related World Regions / Countries Related Global Health Research Topics
According to the current listing, eligibility includes: The program involves Prince of Songkla University and Mahidol University, Thailand, and Methodist Hospital, Houston, Texas, to provide training. Confirm the full requirements in the official notice before applying.
TB/MDR-TB Research Capacity Building in LMICs in Southeast Asia Phase II is funded by Fogarty International Center at the U.S. National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Texas. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article